Abstract
Myeloid malignancies showing CD141+ myeloid dendritic cell (MDC) differentiation have not been documented. Here, we describe a patient with juvenile myelomonocytic leukemia in which a prominent CD141+ cell population was identified most consistent with CD141+ MDCs based on phenotypic similarity with normal CD141+ MDCs. Molecular studies demonstrated a KRAS mutation. The findings from the spleen and bone marrow are described. This is the first well-documented demonstration of CD141+ MDC differentiation of a hematopoietic neoplasm.
Keywords:
CD141; CD1c; Flow cytometry; JMML; Myeloid dendritic cell.
Copyright © 2017 Elsevier Inc. All rights reserved.
MeSH terms
-
Antigens, CD1 / analysis
-
Antigens, Surface / analysis*
-
Biomarkers, Tumor / analysis*
-
Biomarkers, Tumor / genetics
-
Biopsy
-
CD13 Antigens / analysis
-
Cell Differentiation*
-
Child
-
Dendritic Cells / immunology*
-
Dendritic Cells / pathology
-
Flow Cytometry
-
Genetic Predisposition to Disease
-
Glycoproteins / analysis
-
Humans
-
Immunohistochemistry
-
Leukemia, Myelomonocytic, Juvenile / genetics
-
Leukemia, Myelomonocytic, Juvenile / immunology*
-
Leukemia, Myelomonocytic, Juvenile / pathology
-
Leukemia, Myelomonocytic, Juvenile / therapy
-
Male
-
Mutation
-
Phenotype
-
Proto-Oncogene Proteins p21(ras) / genetics
-
Thrombomodulin
Substances
-
Antigens, CD1
-
Antigens, Surface
-
Biomarkers, Tumor
-
CD1C protein, human
-
Glycoproteins
-
KRAS protein, human
-
THBD protein, human
-
Thrombomodulin
-
CD13 Antigens
-
Proto-Oncogene Proteins p21(ras)